Johnson & Johnson (Canada) Inc.
16 meetings with public office holders, May 15, 2025 to Feb 17, 2026.
42 meetings on record since 2023, their first on record.
Meetings over time
- May 2025: 1 meeting, with Ritu Banerjee
- Jun 2025: 0 meetings
- Jul 2025: 0 meetings
- Aug 2025: 0 meetings
- Sep 2025: 1 meeting, with Ritu Banerjee, Greg Orencsak
- Oct 2025: 2 meetings, with Karim Bardeesy, Paul Moen
- Nov 2025: 1 meeting, with Mark Schaan
- Dec 2025: 6 meetings, with Ritu Banerjee, Sandenga Yeba, Greg Orencsak, Sarah Lawley, Pamela Aung-Thin
- Jan 2026: 0 meetings
- Feb 2026: 5 meetings, with Annahat Kochhar, Elizabeth Wong, Maggie Chi, Nora Draper, Justine Frame
May 2025peak 6 in a monthFeb 2026
Hover or focus a month to see who was met.
What they lobby about
- Health16
- Economic Development13
- Industry13
- Internal Trade8
- Research and Development8
- Science and Technology8
- Taxation and Finance8
- Employment and Training4
- Intellectual Property4
- International Trade4
The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.
Who they met
Liberal4 met · 5 meetings
Not in Arena's member list14 met · 19 meetings
- Ritu Banerjee
- Greg Orencsak
- Paul Hebert
- Annahat Kochhar
- Elizabeth Wong
- Jeff Moore
- Justine Frame
- Mark Schaan
- Nora Draper
- Pamela Aung-Thin
- Paul Moen
- Sandenga Yeba
- Sarah Lawley
- Sony Perron
Health Canada (HC) (9) · Innovation, Science and Economic Development Canada (ISED) (9) · Canadian Institutes of Health Research (CIHR) (3) · Treasury Board Of Canada Secretariat (TBS) (1) · Privy Council Office (PCO) (1) · House of Commons (1)
In their own words
- Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
- Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
- Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.